To the Editor: In a recent article, Nathan et al. [1] confirm a strong linear relationship between mean blood glucose (MBG) derived from continuous glucose monitoring (CGM) and HbA 1c in 25 selected individuals observed for 12 weeks. The published study was conducted using CGM to eliminate variation in the relationship between HbA 1c and MBG that might be due to non-representative glucose sampling. Based on the strong association between CGMderived MBG and HbA 1c , the authors advocate that an individual's HbA 1c level is interchangeable with and can be safely interpreted as the estimated MBG based on the population regression equation. They further imply that the high degree of correlation supports the idea that HbA 1c should be 'used universally to adjust therapy'. After carefully reviewing both the authors' data and similar data presented at the European Association for the Study of Diabetes (EASD) annual meeting [2] , we wish to offer an alternative perspective to this 'one size fits all' concept.
The authors' Fig. 1 is a scattergram depicting the relationship between CGM-derived MBG and HbA 1c . A horizontal line across the graph at a MBG of 8 mmol/l identifies two patients with HbA 1c of about 6.5 and 8.0%, respectively [1] . Two patients, same MBG, yet one has a near normal HbA 1c while the other has an unacceptably high HbA 1c . Other examples of between-patient variation in HbA 1c at the same MBG are apparent elsewhere in the figure and in the data presented at the EASD meeting [2] . Nathan et al. had faulted prior studies [3, 4] of the relationship between MBG and HbA 1c for inadequate glucose sampling protocols that may have led to over-or underestimation of the patient's true MBG. In the present study, Nathan et al. overcame the problem of non-representative glucose sampling by using a more intensive glucose sampling protocol over 12 weeks, which would have allowed them to achieve the best possible estimate of a patient's true MBG. Thus, the between-patient variation in HbA 1c at the same MBG found in the data of Nathan et al. is unlikely to be due to inaccurate MBG caused by inadequate sample size or sampling biased to certain times of day. In this respect, the authors' data resemble those reported by the Diabetes Research in Children Network (DirecNet) investigators, who also used CGM and observed between-patient variation in HbA 1c independent of MBG [5] . Between-patient differences in HbA 1c not due to MBG have been well documented in the literature, using less sophisticated glucose sampling protocols but with similar results (citations in [3] and [6] ). In longitudinal studies evaluating repeated measures of MBG and HbA 1c within individuals over time, we have shown that between-patient differences are not due to random variation, but instead track consistently through time and with changes of MBG [3, 6] . Furthermore, these between-patient HbA 1c differences appear to be unrelated to erythrocyte longevity [3] . The widely cited DCCT study followed more than 1400 patients with repeated measures of MBG and HbA 1c every 3 months for up to 9 years [7] . Albeit with a simple glucose sampling protocol, the DCCT also reported an impressive linear association between HbA 1c and MBG [4] . However, large, non-random, consistently repeatable between-patient differ-ences in HbA 1c were readily apparent in the DCCT data at the same MBG [4, 6] .
The demonstration of between-patient HbA 1c differences at the same MBG, whether derived by CGM [1, 2, 5] or other methods, suggests that factor(s) other than blood glucose concentration may also play a role in determining HbA 1c levels [3, 6] . These between-patient differences have additional relevance, since patients with higher than average HbA 1c levels at any given MBG have greater risk for development of microvascular complications in patients with type 1 [6] or type 2 diabetes. Thus the most comprehensive interpretation of HbA 1c for an individual patient should ideally take into account not only the patient's MBG, but also the patient's idiosyncratic characteristics, which cause consistent HbA 1c variance from the mean of the linear regression relationship between HbA 1c and MBG within the population [3, 6] .
The practice of using a patient's HbA 1c as an interchangeable and universally applicable estimate of MBG evolved during the DCCT era. Patients today, however, have ready access to CGM and other sophisticated methods of direct glucose measurement, data storage and calculation of MBG at home that were not available at the time of the DCCT. If the between-patient differences in HbA 1c apparent in the data of Nathan et al. really are due to biological differences between patients, then we predict that there will be large numbers of patients in every diabetes clinic who will repeatedly have major discrepancies between their selfmonitored MBG and the estimated-MBG based on HbA 1c , even if CGM is used to establish the population regression equation. This dissonance will probably be extremely confusing to both patients and their diabetes management team. Furthermore, if HbA 1c -estimated MBG is used as the primary guide for adjusting therapy, patients whose true MBG are overestimated by this equation will be at risk for more frequent episodes of life-threatening hypoglycaemia induced by needlessly aggressive glucose-lowering therapy.
As hypoglycaemia is a major complication of intensive diabetes management [7] , ignoring the possible presence of between-patient variation in the relationship between HbA 1c and MBG is likely to be perilous.
To achieve the most comprehensive and safest interpretation of HbA 1c for patient care, clinicians must recognise that HbA 1c may not be a fully reliable surrogate for MBG. In this case, both patients and clinicians will need to learn how to individualise treatment decisions by taking into account the patient's HbA 1c and preceding self-monitored MBG, as well as idiosyncratic between-patient differences that also contribute to the level of HbA 1c .
